Business
Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges.
About this update from Venus Medtech (hangzhou), Inc. Class H
[{"type":"text","content":"HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges.","length":430,"tagName":"p"},{"type":"text","content":"Key Financial Highlights","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue: RMB471 million, with overseas revenue growing 13.53% YoY to RMB82.5 million.","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted non-IFRS EBITDA loss: Narrowed by 45.56% YoY to RMB254 million, reflecting stringent cost controls.","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Commercial profit: Surged 112.60% YoY to RMB97.7 million, with the commercial profit margin rising from 9.35% (2023) to 20.74%.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin: Remained robust at 78.11%, underscoring pricing stability.","length":72,"tagName":"p"}]}],"tagName":"ol","bulletedList":false,"length":402,"olType":"1"},{"type":"text","content":"Facing a challenging landscape, Venus Medtech reinforced its leadership in China's valvular therapy sector while achieving significant progress in operational efficiency and commercial profitability, mainly reflected in：","length":224,"tagName":"p"},{"type":"text","content":"Cost Optimization","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sales expenses decreased by 18.44% YoY to RMB245 million, with the sales expense ratio decreasing from 61.15% (2023) to 52.05% through streamlined distributor management and accounts receivable reforms.","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"R&D expenses declined 35% YoY to RMB341 million, as the Company prioritized high-value pipeline projects, reducing R&D expense ratio from 106.83% to 72.46%.","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":366,"olType":false},{"type":"text","content":"Profitability Focus","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The &quo...